Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
MaSTherCell
MaSTherCell
Activities:
Manufacturing
Pharmaceutical
Cell & Gene Therapy
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
Catalent adds to regenerative therapy portfolio with $315m acquisition
Belgian CDMO MaSTherCell Global is a technology-focused cell and gene therapy CDMO
Manufacturing
MaSTherCell announces new cell and gene therapy facility in Belgium
The new facility will be built to manufacture late-stage and commercially-approved cell and gene therapy products on the Gosselies Biopark site
Estates & Facilities
Biotech manufacturing services agreement in Europe announced
MaSTherCell will manufacture tumour infiltrating lymphocyte for Iovance’s European late-stage clinical trials
Research & Development
CRISPR Therapeutics and MaSTherCell SA develop allogeneic cell therapies
CRISPR Therapeutics and MaSTherCell SA sign an agreement to develop and manufacture allogeneic CAR-T therapies
Manufacturing
Servier appoints MaSTherCell to develop its cell therapy manufacturing platform
MaSTherCell is developing CAR-T cell therapy manufacturing platform, enabling industrial manufacturing of Servier products
Manufacturing
TxCell signs strategic agreement with MaSTherCell to manufacture cell therapy products
Company commits to an ambitious product development schedule with two discovery platforms
Finance
Orgenesis acquires cell therapy manufacturer MaSTherCell
Acquisition to accelerate type 1 diabetes therapeutic into clinical trials and diversify future business model and product offering
Subscribe now